RESEARCH TRIANGLE PARK, N.C. – June 29, 2016 – Metabolon, Inc., the global leader in metabolomics, announced today that it has awarded fully funded discovery projects to two life sciences researchers, following a competitive application and selection process. The winners are Charles Ruegg, Ph.D., from Eli Lilly and Company and Thaddaeus May, M.D., from Baylor College of Medicine.

Dr. Ruegg’s project is titled “Mechanism of Action: An Exploration of a Novel Inhibitor in Human Plasma Samples Following 28 Days of Treatment.” Dr. May’s project, “Metabolomics of Kwashiorkor Malnutrition,” will focus on understanding the cause of this severe form of acute childhood malnutrition.

“Our goal is to enhance their research through metabolomics to find answers for life-threatening diseases and human health concerns,” said Jay Tolley, Vice President and General Manager of Pharmaceutical and Life Sciences at Metabolon. “We congratulate the award recipients for the work they have done thus far and look forward to successful collaborations on both projects.”

The pilot projects include a metabolomics analysis of all major metabolite classes, including complex lipids. Metabolon will also perform statistical analysis and a thorough biological interpretation of the results.

Metabolomics is the study of small molecules called metabolites and an integral technology for understanding the function of biological systems. By providing a comprehensive picture of the biochemistry, metabolomics is advancing precision medicine and research for translational science, biomarker identification and the study of disease and treatment.

About Metabolon
Metabolon, Inc. is the world’s leading health technology company focused on the use of metabolomics in precision medicine. This powerful tool for assessing health is based on proprietary platforms and informatics that deliver biomarker discoveries, innovative diagnostic tests, and ground-breaking partnerships in genomics-based health initiatives. Metabolon’s expertise is also accelerating research and product development across the pharmaceutical, biotechnology, consumer products, agriculture and nutrition industries, as well as academic and government organizations. Founded in 2000 and headquartered in Research Triangle Park, North Carolina, the company has conducted more than 5,000 independent and collaborative studies, resulting in over 550 peer-reviewed publications. For more information, please visit or follow us on LinkedIn or Twitter.

Cautionary Note about Forward-Looking Statements
The materials provided herein that are not historical facts are or might constitute projections and other forward-looking statements regarding future events that involve substantial risks, uncertainties and assumptions. If any of these risks or uncertainties materialize, or if any of these assumptions prove to be incorrect, Metabolon’s results could differ materially from the results expressed or implied by any forward-looking statements. The risks, uncertainties and assumptions referred to above include, but are not limited to: the uncertainties inherent in biochemical research and development; decisions by regulatory authorities regarding whether and when to approve diagnostic tests; the clinical utility of Metabolon’s metabolomic services; Metabolon’s and its distributors’ ability to successfully commercialize and market both new and existing products; governmental laws and regulations affecting health care, including access, pricing and reimbursement of diagnostic tests; the strength of Metabolon’s intellectual property portfolio; Metabolon’s history of operating losses; whether Metabolon is able to achieve or sustain profitability; its highly competitive industry; its ability to compete effectively; security and privacy risks; and Metabolon’s ability to continue to innovate and provide products and services that are useful to its clients, among other risks, uncertainties and assumptions.


Robin Fastenau
Vice President, Corporate Communications & Investor Relations
Metabolon, Inc.